First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors
This study showed the feasibility of a modified Toxicity Proportion Interval design and PK/PD analysis to determine a recommended dose for a compound without a dose-limiting toxicity and a tolerable and manageable safety profile.
Authors
- Sapna Yadavilli (ORCID: https://orcid.org/0000-0001-6446-5032)
- Víctor Moreno (ORCID: https://orcid.org/0000-0001-6099-4236)
- Frans L. Opdam (ORCID: https://orcid.org/0000-0002-9489-6535)
- Michele Maio (ORCID: https://orcid.org/0000-0002-0323-6321)
- Aaron R. Hansen (ORCID: https://orcid.org/0000-0002-2363-8707)
- David C. Turner (ORCID: https://orcid.org/0000-0001-9242-6188)
- Iván Díaz-Padilla
- Eric Angevin (ORCID: https://orcid.org/0000-0001-6249-7209)
- Catherine Elizabeth Ellis (ORCID: https://orcid.org/0009-0008-7635-7846)
- Todd Michael Bauer (ORCID: https://orcid.org/0000-0002-3078-5043)
- Steven Hirschfeld (ORCID: https://orcid.org/0000-0003-0627-7249)
- Juan Martín-Liberal (ORCID: https://orcid.org/0000-0003-2552-5172)
- Danny Rischin (ORCID: https://orcid.org/0000-0002-3368-0386)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Christophe Le Tourneau (ORCID: https://orcid.org/0000-0001-9772-4686)
- Marc Ballas (ORCID: https://orcid.org/0009-0001-3430-3742)
- Helen Zhou (ORCID: https://orcid.org/0009-0007-8538-1234)
Institutions
- University of Siena (IT)
- Hebron University (PS)
- Université de Bordeaux (FR)
- Université Paris-Saclay (FR)
- Dutch Cancer Society (NL)
- Age UK (GB)
- Peter MacCallum Cancer Centre (AU)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- The Netherlands Cancer Institute (NL)
- Institut des Neurosciences Paris-Saclay (FR)
- Network Italiano Per la Bioterapia Dei Tumori (IT)
- GlaxoSmithKline (United States) (US)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Institut Bergonié (FR)
- Tennessee Oncology (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1136/jitc-2025-011475
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09